PR Newswire | Apr 20, 2021 04:31PM EDT

5, 2021

04/20 15:30 CDT

Vanda Pharmaceuticals to Announce First Quarter 2021 Financial Results on May 5, 2021Conference Call and Webcast to Follow WASHINGTON, April 20, 2021

WASHINGTON, April 20, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2021 on Wednesday, May 5, 2021, after the market closes.

Vanda will host a conference call at 4:30 PM ET on Wednesday, May 5, 2021, during which management will discuss the first quarter 2021 financial results and other corporate activities. To participate in the conference call, please dial 1-866-688-9426 (domestic) or 1-409-216-0816 (international) and use passcode 5709209.

The conference call will be broadcast simultaneously and archived on Vanda's website, www.vandapharma.com. Investors should go to the website at least 15 minutes early to register, download, and install any necessary audio software.

A replay of the call will be available on Wednesday, May 5, 2021, beginning at 7:30 PM ET and will be accessible until Wednesday, May 12, 2021, at 7:30 PM ET. The replay call-in number is 1-855-859-2056 for domestic callers and 1-404-537-3406 for international callers. The passcode number is 5709209.

About Vanda Pharmaceuticals Inc.

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on Twitter @vandapharma.

Corporate Contact:AJ Jones II Chief Corporate Affairs and Communications Officer Vanda Pharmaceuticals Inc. 202-734-3400 pr@vandapharma.com

Elizabeth Van EveryHead of Corporate Affairs Vanda Pharmaceuticals Inc. 202-734-3400 pr@vandapharma.com

View original content: http://www.prnewswire.com/news-releases/vanda-pharmaceuticals-to-announce-first-quarter-2021-financial-results-on-may-5-2021-301273128.html

SOURCE Vanda Pharmaceuticals Inc.